真是19年的四个关键所在班次，它将在发展几现已朔造整形外科整形手术仪器人贸易市场。

近些年医疔仪器设备服务行业最红门的卖场之五是内科工具人。按照其Allied Market Research的弄一份检测结果，该业务领域卖场服务器在201六年为0.562亿欧元，预估到2025年将成长至987.37亿人民币 ，預測过后的塑料年成长率为8.5%。二零一九年是产科电脑人方法的席卷持续增长元年。MD+DI公众号介绍了二零一九年内窥镜手术电脑人邻域八个重要的时时。

达芬奇电脑人：扎实推进下降攻略

潜意识整形美容外科自2000年刷出FDA批准书纳斯达克上市之初，一直以来都是微创产品设备人卖场的邻导者。以至于，角逐争夺者现已迅速展现并上升。潜意识整形美容外科的企业高管表达出来，跟随着角逐越做越越强烈，新产品开发设备的还推出，集团有可能会按照“落价手段”来兑换更强的整个市场，也还是增添成本商务商务谈判和商务商务谈判精力的延伸。该我司说道，这样的最新也会出现提成冲击。但谈谈有一些原来我认为其价格过高的医药和医药心中认为，会是个号qq信息。

CMR的几大凯旋

總部应用于国外剑桥的CMR2018年过得出色。5哪个月，品牌在C轮银行融资中募集了2.4三亿元，主要用于它的器机人手游辅助整形安全装置服务业化。下十一个月，该新公司来完成了向处于新加坡普纳的星空照护医院门诊（Galaxy Care Hospital）卖其首台系统的进行交易。CMR创办于5节前，并在媒介渠道上信息公开表述，盼望下一年能得以FDA的认可度。

Verb：新CEO就任

Verb是强生厂家的Ethicon相关部们和verly生活是什么专业的厂家的合资厂家厂家。仅仅进行配合产生在verly（前谷歌浏览器生活是什么专业的相关部们）与有很多医疗器械科学技术厂家进行配合的阶段。现在Verb在揭牌之初就独树一帜，但该厂家在二零一九年一支很大沉静。所以，去年6月，Verb多次成了头条新鲜事了新鲜事了，起初它正式宣布库尔特•阿扎尔巴津（Kurt Azarbarzin）将就任新腹黑总裁兼首席总裁下达官。阿扎尔巴津曾是SurgiQuest的顶尖连接官，到了202007年被Conmed（康美）以2.66亿外币收购厂家。Azarbarzin都是个品牌英雄，他接班了Verb前顶尖连接官ScottHuennekens，二者于2018年年后离厂家。

泰坦医疗设备（Titan Medical）：禁止发掘

泰坦医疗保健平台（Titan Medical）在健身运动丝机人内窥镜手术系统的上碰上好几回个大的缺陷，并在1月下旬即日起撤销所有关于该软件平台代价和事件的預測，提前结束开拓。Titan Medical带表，贷款不佳是会造成推后的根本原因。因此，泰坦并没得让它终止。该我司正，都希望能寻求募集2300万澳元的资金量，以好处这个运转的系统化返回走上正轨。

XACT：获得了FDA的市场销售准许

XACT机械设备人企业的治疗机械设备人拥有FDA纳斯达克上市获准。该器在CT正确引导下经皮干预冶疗阶段中足以用。这个总店应用于印度的治疗机械设备人集团，反面的让人觉得赞不绝口的缘由是，它是第一例对于图形开发计划和网站导航，不用办理人工机械控制的设计人设计，才可以自动式疏导各项测试仪器在一类型临床实践广泛应用和适合症中进行进到这一领域和转弯控制。

强生：34亿欧元回收Auris

强生以34亿美金库存现金（大概为人们币2305亿）对价使用整形POS机人工司Auris，如果你超过那些飞机航程碑，还要网银支付有且仅有23.3亿外币的另外或有钱款。这也将变为强生在购置急诊科术APP机器设备人技术性开发管理单位Orthotaxy阔别三多年后再一次在某一方向的进攻。

Auris 是由普外产品人先行者弗里德里克·莫尔（Frederic Moll）诞生，他同样也是中国治疗机械人领先Intuitive Surgical（主观美容外科）的共同创使人之三，另外一个的达芬奇机械人现掌控了过大分额的贸易市场。Frederic Moll也在大量收购后假如强生。

Auris用心于1.肺癌丝机人技木，其重要新产品就是一款名是Monarch的，可由美容外科护士按照某个掌握器完成掌握的丝机人，指引某个有点摄录机的看镜进到患病者休内，适用于原因性和诊疗性的支气管镜观察，在这种观察中护士需将分析仪器复制患病者的鼻内或口腔医院。

美敦力：建造医疗保健服务器人王国

九月24日，美敦力在股权出资方联席会议上发布了了其新一批微创丝机人Hugo RAS。Hugo RAS选用控制智能化的改善规划，内容解决近视手术广州POS机人投入和利用的困难。

美敦力工厂优化微调方式小组内实行副经理裁兼总截鲍勃·怀特说：“这只是仅是正式发布是一款最火款式POS机人，人们是要开发POS机人帝国下载。”

2018111月29日，美敦力就发出以17亿外币（大概为国民币120万美元）高价回收俄罗斯医辽机机械设备机械设备司Mazor Robotics还有机机械设备人辅助性工具做内窥镜手术渠道，该司通常产品的为Mazor X制导机械设备和Renaissance机机械设备人辅助性工具脊椎做内窥镜手术机机械设备机械设备。

在回收进行后的一两六个月，美敦力在英国面世了Mazor X Stealth™机气人辅助制作脊椎骨整形网上平台。

Mazor X Stealth™ 设备人机平台将美敦力的Stealth平台与Mazor主要的设备人高技术相切合。实现人机交互式三维图发展规划和短信机平台给予实时路况画面进行，交互式和网站导航，给予事情具体流程可推测性和协调性性。它安全使用3D网络摄像头头，进行标记符号和机械设备臂，以持续性控制产品和检测设备在脊椎骨的位址，并进度计划怎么写透彻准确定位同旁内角。

美敦力最新信息第三季度、半年度（2020财年第一次第三季度、半年度）业绩预告表现，在脊椎销售部门的提升中，整形手术产品人目前在对脊椎销售部门提升起着拉高角色。

在境内，监管监督管理监督管理同一也在血盘推助社区医学广州POS机人的通过。《我们研制2025》中，生物学健康安全和高效能社区医学器具是重中之重冲破的六大这个领域组成。《2017-202五年我们动手术广州POS机人产业链激烈竞争情况及未来十年提升浪潮报告模板》彰显，未来十年目前小手术服务器人的互联网行业产值将在202一年走到200亿。

而做手术仪器人相对骨外科种植物茶叶市场的拉动能愈来愈大，也成为各个骨外科国内巨头的必争之城。

译文如下所述：

One of the hottest markets in the medical device industry right now is surgical robotics. The space, valued at $56.3 million in 2017, is expected to grow to $98,737 million by 2024 with a CAGR of 8.5% during the forecast, according to a report from Allied Market Research. Growth is happening now and 2019 has been a breakout year for surgical robotics – from product unveilings to delays. MD+DI is counting down the Top 7 developments for Surgical Robotics in 2019.

The Art of Negotiation

For years Intuitive Surgical has been at the top of the surgical robotics market – having gained a nod from FDA for the da Vinci Robot in 2000. (Whew that’s a lot of lead time.) However, competitors are>increased price negotiations and elongated negotiation timelines as competition gets closer to launching new products. The company said these dynamics could also result in profit fluctuations. This could be a plus for some hospitals and healthcare centers that have had issues with the da Vinci’s pricing.

CMR’s Two Big Wins

Cambridge, UK-based CMR has had a good year. In September, the company raised $243 million (wow!) in a Series C round to commercialize its Versius robot-assisted surgery device. And then last month the company completed the sale of its first unit to the Galaxy Care Hospital in Pune, India. CMR was founded 5 years ago and has publicly stated in media outlets that it hopes to have a nod from FDA next year.

Verb’s New Leadership

Verb is a joint venture between Johnson & Johnson’s Ethicon Unit and Verily Life Sciences. The collaboration happened during the time when Verily (the former life sciences unit of Google) was partnering with numerous companies in the medtech and pharmaceutical space. While Verb made a big splash when it was first formed, the company has been fairly quiet in 2019. However, in June Verb>

When Titan Hit Pause

Titan Medical hit a huge roadblock with the Sport robotic surgical system and announced in mid-October that it was withdrawing all forecasts with respect to the cost and timing of the platform. The Toronto-based company said a lack of financing was the reason behind the delay. Titan isn’t letting this stop it, however. The company is seeking to raise $25 million in an offering that could help get the Sport’s system back>

XACT Brings Home OK from FDA

XACT Robotics secured a coveted FDA nod for its robotic system. The device was cleared for use during CT-guided percutaneous interventional procedures. The wow factor behind the Caesarea, Isreal-based company’s robot is that it is the first hands-free robotic system combining image-based planning and navigation with the insertion and steering of various instruments across an array of clinical applications and indications.

Johnson & Johnson’s Glow Up in Surgical Robotics

Johnson & Johnson pulled off>Frederic Moll, M.D., CEO and Founder of Auris Health, joined J&J. Moll is also known for cofounding Intuitive Surgical. With this acquisition and J&J’s Verb the company now has multiple shots>

Medtronic’s Done Dropping Hints

Medtronic teased us all year long with tidbits and hints about its upcoming soft-tissue surgical robotics system. After some delays in 2018 with scant details about the platform, the Dublin-based company opened up a bit in June with the announcement of a collaboration with Karl Storz. The firm said its upcoming robotic-assisted surgical platform would incorporate Karl Storz’s 3D vision systems and visualization components. To boot the two companies had been working style="box-sizing: border-box; background-color: transparent; color: rgb(0, 184, 214); text-decoration: none; font-weight: bold;">announced in August it would unveil the robot during an investor’s meeting in September. And that it did. After a lengthy demonstration, Medtronic said it anticipates submitting for CE mark in the Q1 of the company's fiscal year 2021 (Medtronic's fiscal year begins in April), and filing for a U.S. investigational device exemption to begin placing systems in U.S. hospitals, training surgeons, and gathering clinical data in the first half of its fiscal year 2021. If all goes as planned, the system could be available both in Europe and in the U.S. within the next 24 months.